Abstract	O

Objective	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
hydroxychloroquine	O
(	O
HCQ	O
)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
moderate	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
.	O

Methods	O
:	O
We	O
prospectively	O
enrolled	O
30	O
treatment	O
-	O
naÃ¯ve	O
patients	O
with	O
confirmed	O
COVID	O
-	O
19	O
after	O
informed	O
consent	O
at	O
Shanghai	O
Public	O
Health	O
Clinical	O
Center	O
.	O

The	O
patients	O
were	O
randomized	O
1	O
:	O
1	O
to	O
HCQ	O
group	O
and	O
the	O
control	O
group	O
.	O

Patients	O
in	O
HCQ	O
group	O
were	O
given	O
HCQ	O
400	O
mg	O
per	O
day	O
for	O
5	O
days	O
plus	O
conventional	O
treatments	O
,	O
while	O
those	O
in	O
the	O
control	O
group	O
were	O
given	O
conventional	O
treatment	O
only	O
.	O

The	O
primary	O
endpoint	O
was	O
negative	B-PrimaryOutcome
conversion	I-PrimaryOutcome
rate	I-PrimaryOutcome
of	I-PrimaryOutcome
SARS	I-PrimaryOutcome
-	I-PrimaryOutcome
CoV	I-PrimaryOutcome
-	I-PrimaryOutcome
2	I-PrimaryOutcome
nucleic	I-PrimaryOutcome
acid	O
in	O
respiratory	O
pharyngeal	O
swab	O
on	B-TimeFrame
days	I-TimeFrame
7	I-TimeFrame
after	I-TimeFrame
randomization	I-TimeFrame
.	O

This	O
study	O
has	O
been	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Shanghai	O
Public	O
Health	O
Clinical	O
Center	O
and	O
registered	O
online	O
(	O
NCT04261517	O
)	O
.	O

Results	O
:	O
One	O
patient	O
in	O
HCQ	O
group	O
developed	O
to	O
severe	O
during	O
the	O
treatment	O
.	O

On	O
day	O
7	O
,	O
nucleic	O
acid	O
of	O
throat	O
swabs	O
was	O
negative	O
in	O
13	O
(	O
86	O
.	O
7	O
%	O
)	O
cases	O
in	O
the	O
HCQ	O
group	O
and	O
14	O
(	O
93	O
.	O
3	O
%	O
)	O
cases	O
in	O
the	O
control	O
group	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
median	B-OtherOutcome
duration	I-OtherOutcome
from	I-OtherOutcome
hospitalization	I-OtherOutcome
to	O
virus	O
nucleic	O
acid	O
negative	O
conservation	O
was	O
4	O
(	O
1	O
,	O
9	O
)	O
days	O
in	O
HCQ	O
group	O
,	O
which	O
is	O
comparable	O
to	O
that	O
in	O
the	O
control	O
group	O
[	O
2	O
(	O
1	O
,	O
4	O
)	O
days	O
,	O
Z	O
=	O
1	O
.	O
27	O
,	O
P	O
>	O
0	O
.	O
05	O
]	O
.	O

The	O
median	B-OtherOutcome
time	I-OtherOutcome
for	I-OtherOutcome
body	I-OtherOutcome
temperature	I-OtherOutcome
normalization	I-OtherOutcome
in	O
HCQ	O
group	O
was	O
1	O
(	O
0	O
,	O
2	O
)	O
day	O
after	O
hospitalization	O
,	O
which	O
was	O
also	O
comparable	O
to	O
that	O
in	O
the	O
control	O
group	O
[	O
1	O
(	O
0	O
,	O
3	O
)	O
day	O
]	O
.	O

Radiological	B-OtherOutcome
progression	I-OtherOutcome
was	I-OtherOutcome
shown	I-OtherOutcome
on	I-OtherOutcome
CT	I-OtherOutcome
images	I-OtherOutcome
in	O
5	O
cases	O
(	O
33	O
.	O
3	O
%	O
)	O
of	O
the	O
HCQ	O
group	O
and	O
7	O
cases	O
(	O
46	O
.	O
7	O
%	O
)	O
of	O
the	O
control	O
group	O
,	O
and	O
all	O
patients	O
showed	O
improvement	O
in	O
follow	O
-	O
up	O
examinations	O
.	O

Four	O
cases	O
(	O
26	O
.	O
7	O
%	O
)	O
of	O
the	O
HCQ	O
group	O
and	O
3	O
cases	O
(	O
20	O
%	O
)	O
of	O
the	O
control	O
group	O
had	O
transient	O
diarrhea	O
and	O
abnormal	O
liver	O
function	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Conclusions	O
:	O
The	O
prognosis	O
of	O
COVID	O
-	O
19	O
moderate	O
patients	O
is	O
good	O
.	O

Larger	O
sample	O
size	O
study	O
are	O
needed	O
to	O
investigate	O
the	O
effects	O
of	O
HCQ	O
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
.	O

Subsequent	O
research	O
should	O
determine	O
better	O
endpoint	O
and	O
fully	O
consider	O
the	O
feasibility	O
of	O
experiments	O
such	O
as	O
sample	O
size	O
.	O

